Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment


ABSTRACT: Biological replicates of liver spheroids derived from primary hepatocytes were treated with IFNa2 and/or baricitinib for 24 h and subsequently infected with Sars-CoV-2. The cells were harvested 48 h time after infection. Total RNA was extracted and sequenced with a strand-specific paired end RNA-seq protocol.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens

SUBMITTER: Claudia Kutter 

PROVIDER: E-MTAB-9711 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

Stebbing Justin J   Sánchez Nievas Ginés G   Falcone Marco M   Youhanna Sonia S   Richardson Peter P   Ottaviani Silvia S   Shen Joanne X JX   Sommerauer Christian C   Tiseo Giusy G   Ghiadoni Lorenzo L   Virdis Agostino A   Monzani Fabio F   Rizos Luis Romero LR   Forfori Francesco F   Avendaño Céspedes Almudena A   De Marco Salvatore S   Carrozzi Laura L   Lena Fabio F   Sánchez-Jurado Pedro Manuel PM   Lacerenza Leonardo Gianluca LG   Cesira Nencioni N   Caldevilla Bernardo David D   Perrella Antonio A   Niccoli Laura L   Méndez Lourdes Sáez LS   Matarrese Daniela D   Goletti Delia D   Tan Yee-Joo YJ   Monteil Vanessa V   Dranitsaris George G   Cantini Fabrizio F   Farcomeni Alessio A   Dutta Shuchismita S   Burley Stephen K SK   Zhang Haibo H   Pistello Mauro M   Li William W   Romero Marta Mas MM   Andrés Pretel Fernando F   Simón-Talero Rafaela Sánchez RS   García-Molina Rafael R   Kutter Claudia C   Felce James H JH   Nizami Zehra F ZF   Miklosi Andras G AG   Penninger Josef M JM   Menichetti Francesco F   Mirazimi Ali A   Abizanda Pedro P   Lauschke Volker M VM  

Science advances 20210101 1


Using AI, we identified baricitinib as having antiviral and anticytokine efficacy. We now show a 71% (95% CI 0.15 to 0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age, 81 years). An additional 48 cases with mild-moderate pneumonia recovered uneventfully. Using organotypic 3D cultures of primary human liver cells, we demonstrate that interferon-α2 increases ACE2 expression and SARS-Co  ...[more]

Similar Datasets

2016-09-28 | E-MTAB-4444 | biostudies-arrayexpress
2023-10-24 | E-MTAB-11858 | biostudies-arrayexpress
2015-03-27 | E-GEOD-67330 | biostudies-arrayexpress
2023-08-09 | E-MTAB-12505 | biostudies-arrayexpress
2021-03-02 | E-MTAB-8799 | biostudies-arrayexpress
2017-03-31 | E-MTAB-5059 | biostudies-arrayexpress
2008-10-31 | E-GEOD-8448 | biostudies-arrayexpress
2022-01-01 | E-MTAB-8907 | biostudies-arrayexpress
2024-02-16 | PXD036798 | Pride
2018-04-05 | E-MTAB-5964 | biostudies-arrayexpress